Clinical trials: SCHIZOPHRENIA 1 (Disorder)
Schizophrenia
Reboxetine Adjuvant Therapy for the Treatment of Schizophrenia
30 patients will randomly be selected and will be administered either reboxetine or a placebo. changes in cognition and behavior will be assessed by computer tests and scales during a six week study period.
- Trial name
- NCT00409201
- Testing
- reboxetine adjuvant therapy
- Where
- 2 sites in Israel
- Volunteers
- 30 people
- Sponsor
- Abarbanel Mental Health Center
Schizophrenia
β-Cell Function in Schizophrenic Subjects on Atypical Antipsychotic drugS
The purpose of this study is to determine whether atypical antipsychotic drugs (commonly prescribed for treating schizophrenia) induce changes in anthropometry and metabolism, including alteration in insulin sensitivity and/or…
- Trial name
- SANAT (NCT00528359)
- Testing
- quetiapine or olanzapine or risperidone or aripiprazole
- Where
- Belgium
- Volunteers
- 36 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Early Course Schizophrenia Spectrum Disorder
A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia
This study will test whether CVL-562 (PF-06412562), a dopamine 1 partial agonist novel compound, affects working memory neural circuits in patients with early episode schizophrenia.
- Trial name
- NCT04457310
- Testing
- CVL-562 (PF-06412562) 1 mg, CVL-562 (PF-06412562) 4 mg, CVL-562 (PF-06412562) 15 mg
- Where
- 4 sites in United States
- Volunteers
- 112 people
- Sponsor
- Yale University
Schizophrenia, Schizoaffective Disorder
A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to assess the time for patients to relapse when switched from an oral antipsychotic to one of two doses of long-acting risperidone injection (shots).
- Trial name
- NCT00297388
- Testing
- Risperidone, long-acting injectable
- Volunteers
- 40 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Healthy
A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999
The purpose of this study is to assess the bioavailability, safety, and tolerability of a modified-release formulation of PF-05180999 relative to an immediate-release formulation in healthy adult subjects.
- Trial name
- NCT01530529
- Testing
- PF-05180999
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
SCHIZOPHRENIA 1 (Disorder)
Effect of Fluvoxamine on Cognition, Behavior, Symptoms and mRNA and Protein Expression in Schizophrenia Patients
The purpose of this study is to determine effect of Fluvoxamine augmentation on cognitive function , aggressive behavior , clinical symptoms and mRNA (messenger ribonucleic acid) and protein expression in human peripheral…
- Trial name
- NCT01832285
- Testing
- fluvoxamine
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Sha'ar Menashe Mental Health Center
Agitation, Schizophrenia
Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department
This is a single-arm pilot study to examine the impact of BXCL501 (sublingual film formulation of dexmedetomidine) administration on reducing the severity of undifferentiated acute agitation in patients presenting to the…
- Conditions
- Agitation, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
- Trial name
- NCT05974527
- Testing
- Sublingual film containing dexmedetomidine (BXCL501)
- Sponsor
- Brigham and Women's Hospital
Alcohol Use Disorder, Alcohol Abuse/Dependence
Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), approved for the treatment of type 2 diabetes and obesity, have shown promise as a novel treatment for alcohol use disorder (AUD).
- Conditions
- Alcohol Use Disorder, Alcohol Abuse/Dependence, Alcohol Dependence, Alcoholism
- Trial name
- DUALPSYCHIATRY (NCT06939088)
- Testing
- Tirzepatide
- Where
- 2 sites in Denmark
- Volunteers
- 108 people
- Sponsor
- Anders Fink-Jensen, MD, DMSci
Healthy Volunteers, Schizophrenia
Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of TAK-041: 1. Following oral single and multiple doses in healthy participants. 2.
- Trial name
- NCT02748694
- Testing
- TAK-041
- Where
- United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Neurocrine Biosciences
Bipolar 1 Disorder, Schizophrenia Disorder
An Expanded Access Program (EAP) for OLZ/SAM in Pediatric Participants With Schizophrenia or Bipolar I Disorder (ALKS 3831-315)
To provide continued access to OLZ/SAM for pediatric participants with schizophrenia or bipolar I disorder who have completed participation in the ALKS 3831-A313 long-term safety extension study.
- Trial name
- NCT07744113
- Testing
- OLZ/SAM
- Where
- United States
- Sponsor
- Alkermes, Inc.
Coronary Disease, Myocardial Infarction
Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave
The CLIMATE-III Observational Study examines to what extent chronically ill patients experience adverse health effects because of heat and whether the patients' specific health behavior, somatosensory amplification, risk and…
- Conditions
- Coronary Disease, Myocardial Infarction, Heart Failure, Arrhythmias, Cardiac
- Trial name
- CLIMATE-III (NCT06890208)
- Testing
- No intervention
- Where
- Germany
- Volunteers
- 176 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Cognitive Impairment, Schizophrenia
Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults
The purpose of this study is to determine if eltoprazine (as an adjunct to anti-psychotic medication) improves one or more aspects of cognitive impairment in adult schizophrenic patients.
- Trial name
- NCT01266174
- Testing
- Eltoprazine
- Where
- 6 sites in United States
- Volunteers
- 31 people
- Sponsor
- Amarantus BioScience Holdings, Inc.
SCHIZOPHRENIA 1 (Disorder), Sensory Perceptual Characteristics
Precision HD-tACS for Enhancing Sensory Experience in Schizophrenia
To ensure unified sensory perception, the brain must link information from different senses across time and space. This unification of perception often referred to as a perceptual "binding constraint" is a prerequisite for any…
- Trial name
- TherACles (NCT07632261)
- Testing
- Transcranial neurostimulation
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Hôpital le Vinatier
Psychotic Disorders
This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year
This is a study in people between 16 and 30 years of age who have a specific type of mental illness called attenuated psychosis syndrome (APS).
- Trial name
- NCT03230097
- Testing
- BI 409306
- Where
- 33 sites in United States, Canada and 2 more
- Volunteers
- 50 people
- Sponsor
- Boehringer Ingelheim
SCHIZOPHRENIA 1 (Disorder)
Brain Imaging of DSP-2342
The investigators aim to determine the effects of a novel drug on brain function and brain chemistry in patients with schizophrenia.
- Trial name
- NCT07850102
- Testing
- DSP-2342
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Johns Hopkins University
Schizophrenia and Disorders With Psychotic Features
One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome
The purpose of this study is to explore the impact of ziprasidone on the distribution of metabolic syndrome risk factors in a population of patients presenting with glucose intolerance, dyslipidemia and/or elevated waist…
- Trial name
- NCT00748566
- Testing
- Ziprasidone HCL (oral)
- Where
- 32 sites in Canada
- Volunteers
- 172 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242
This study involves evaluating the occupancy of ATI-9242 at steady state at three different dose levels on D2 receptors in the brain using [18F] Fallypride PET in up to three cohorts of subjects.
- Trial name
- NCT02824666
- Testing
- ATI-9242, [18F]Fallypride Imaging
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Braeburn Pharmaceuticals
Schizophrenia, Bipolar 1 Disorder
Abilify Maintena PMS in Schizophrenia Patients or Bipolar 1 Disorder
This is a Post-Marketing Surveillance (PMS) of Abilify Maintena® Injections in accordance with Korean regulations on New Drug Re-examination (i.e.
- Trial name
- NCT03386851
- Where
- South Korea
- Volunteers
- 1,030 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation
The purpose of this study is to estimate the proportion of participants fulfilling criteria for symptomatic remission following a transition to 12 months treatment with flexible-dose paliperidone palmitate 3 month formulation…
- Trial name
- NCT02713282
- Testing
- Paliperidone palmitate 3 month formulation (PP3M)
- Where
- 46 sites in Croatia, Denmark and 13 more
- Volunteers
- 306 people
- Sponsor
- Janssen-Cilag Ltd.
Psychosis, Schizo Affective Disorder
TOPUS - Testing an Implemented Intervention to Reduce Duration of Untreated Psychosis
This study examines whether an early-detection program for psychosis can shorten the time patients remain untreated after the first appearance of psychotic symptoms, and whether such a reduction improves later functioning for…
- Conditions
- Psychosis, Schizo Affective Disorder, SCHIZOPHRENIA 1 (Disorder)
- Trial name
- TOPUS (NCT07716969)
- Testing
- No intervention (Observational Study)
- Where
- 2 sites in Denmark
- Volunteers
- 250 people
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital